Novo buys three non-incretin obesity programs from Kallyope
Danish drugmaker Novo (NOV: N) has added three early-stage obesity programs to its pipeline through an asset purchase agreement with Kallyope, a privately held New York biotech company. The deal was disclosed on Friday in a LinkedIn post by Jacob Petersen, Novo's head of global research, and covers non-incretin approaches to weight loss rather than the gut hormones behind today's leading treatments.
The programs sit outside the incretin class of gut hormones that includes GLP-1 medicines such as Novo's obesity blockbuster Wegovy (semaglutide). By reaching for different biological mechanisms, Novo is hedging against the nausea and weight regain that can follow incretin treatment, and widening the range of options it might offer patients with different needs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze